Aptevo Q2: mipletamig 81% remission in AML; Niowave 50/50 radiopharma deal

Aptevo Therapeutics Inc.

Cash $9.8M at June 30, 2026; raised $0.6M under Yorkville SEPAs in Q2.
Mipletamig: 87% clinical benefit rate, 81% remission rate in 31 frontline AML patients; 55% MRD neg, 36% TP53, 6 bridged to transplant.
Appointed Mary J. Janatpour, Ph.D. as SVP and Chief Scientific Officer.
Secured $1.5M non-dilutive grant from Andy Hill CARE Fund for APVO451 IND-enabling work; candidate selection by year-end 2026.
Entered 50/50 collaboration with Niowave for up to three radiopharmaceutical programs; Niowave took 7.9% equity stake (up to 19.99%).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.